Abstracts tagged "autoantibodies"

Abstract Number: 578 • 2016 ACR/ARHP Annual Meeting
Do Specific Anti-Citrullinated Antibodies Predict Different Phenotype of Rheumatoid Arthritis?
Mikael Brink¹, Monika Hansson², Linda Mathsson-Alm^3,4, Johan Rönnelid⁵, Karl Skriner⁶, Guy Serre⁷, Lars Klareskog² and Solbritt Rantapää-Dahlqvist¹, ¹Rheumatology, Umeå University, Umeå, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³ThermoFisher Scientific, Uppsala, Sweden, Uppsala, Sweden, ⁴Thermo Fisher Scientific, Uppsala, Sweden, ⁵Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁶Humboldt University of Berlin, Berlin, Germany, ⁷Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France
Background/Purpose: Antibodies against cyclic citrullinated peptides (anti-CCP) have been suggested to identify a more severe phenotype of rheumatoid arthritis. In this study we have analysed…
Abstract Number: 1603 • 2016 ACR/ARHP Annual Meeting
Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis
Laura Cappelli¹, J. Lynn Palmer² and Clifton Bingham III³, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²CORRONA Research Foundation, Phoenix, AZ, ³Johns Hopkins University, Baltimore, MD
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis Background/Purpose: Biologic medications have improved outcomes for patients with rheumatoid arthritis (RA), but little…
Abstract Number: 2707 • 2016 ACR/ARHP Annual Meeting
Autoantibodies Against CD74 – a New Diagnostic Marker for Spondyloarthritis (SpA)
Torsten Matthias¹, Eva Schweikhard², Sandra Reuter¹, Maria Köhler³, Joachim Georgi³, Niklas Thomas Baerlecken⁴ and Torsten Witte⁵, ¹Aesku.Kipp.Institute, Wendelsheim, Germany, ²Aesku.Diagnostics, Wendelsheim, Germany, ³Department of Internal medicine and Rheumatology, Helios Ostseeklinik Damp, Germany, Damp, Germany, ⁴Clinical Immunology and Rheumatology, MD, Hannover, Germany, ⁵Hannover Medical School, Hanover, Germany
Background/Purpose: Spondyloarthritis (SpA) is a common debilitating inflammatory disorder. Pathogenesis of axial SpA (axSpA) including ankylosing spondylitis (AS) is still largely unclear. Diagnosis is difficult,…
Abstract Number: 661 • 2016 ACR/ARHP Annual Meeting
Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction
Magdalena Sroka¹, Indranil Biswas¹, Brian Shepherd¹, Dat C Truong², Harini Bagavant¹ and Umesh S Deshmukh¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma, Norman, OK
Background/Purpose: Circulating autoantibodies reactive against Ro52 are detected in the sera of 70% of patients with Sjögren’s syndrome (SS), and their presence has been associated…
Abstract Number: 1781 • 2016 ACR/ARHP Annual Meeting
Analysis of Influences of Various Factors on the Prognosis of Acute Confusional State of Diffuse Psychiatric/Neuropsychological Syndromes in Systemic Lupus Erythematosus
Gakuro Abe¹, Yoshiyuki Arinuma¹, Hirotoshi Kikuchi² and Shunsei Hirohata¹, ¹Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE), especially diffuse psychiatric/neuropsychological syndromes (diffuse NPSLE), is one of the most difficult complications of the disease. For the evaluation…
Abstract Number: 2808 • 2016 ACR/ARHP Annual Meeting
Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus
Shunsei Hirohata¹, Yuko Sakuma², Tamiko Yanagida³ and Taku Yoshio⁴, ¹Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ³Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁴Jichi Medical University, Tochigi, Japan
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…
Abstract Number: 669 • 2016 ACR/ARHP Annual Meeting
RNA-Sequencing Reveals Sjogren’s Syndrome Anti-Ro Negative Patients Share Similar Pathways to Multiple Sclerosis Patients
Indra Adrianto¹, John Ice¹, Astrid Rasmussen², Courtney Montgomery¹, R. Hal Scofield¹, Gabriel Pardo¹, Kathy Sivils¹, Robert Axtell¹ and Christopher Lessard¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease characterized by autoantibodies to Ro and/or La proteins and lymphocytic infiltration into exocrine glands. Multiple sclerosis (MS)…
Abstract Number: 1834 • 2016 ACR/ARHP Annual Meeting
Commensal Ro60 Autoantigen Ortholog Cross-Reactivity in Human Lupus and Gnotobiotic Models
Teri Greiling¹, Carina Dehner², Stephen Renfroe³, Xinguo Chen⁴, Kevin Hughes⁴, Silvio M. Vieira³, William Ruff³, Marco Boccitto⁴, Andrew Goodman⁵, Sandra L. Wolin⁴ and Martin Kriegel^3,6, ¹Dermatology and Immunobiology, Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, new haven, CT, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Cell Biology, Yale School of Medicine, New Haven, CT, ⁵Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁶Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: The earliest autoantibodies in lupus are directed against the autoantigen Ro60, an RNA binding protein with orthologs that we identified in a subset of…
Abstract Number: 2819 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Anti-Aquaporin 4 Antibody Measurement in Patients with Neuropsychiatric Systemic Lupus Erythematosus with Neuromyelitis Optica Spectrum Disorder Manifestations
Simone Mader¹, Yoshiyuki Arinuma¹, Venkatesh Jeganathan¹, Yuichiro Fujieda², Irena Dujmovi³, Jelen Drulovic³, Yuko Sakuma⁴, Shinsuke Yasuda⁵, Joel Stern⁶, Cynthia Aranow⁶, Meggan Mackay⁷, Tatsuya Atsumi⁵, Shunsei Hirohata⁸ and Betty Diamond⁹, ¹Center of Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ²Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Clinical Centre of Serbia University School of Medicine, Belgrade, Serbia, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁵Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁶The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁸Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁹Autoimmune & Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by the presence of autoantibodies. Among the complications of SLE, neuropsychiatric manifestations (NPSLE) can…
Abstract Number: 791 • 2016 ACR/ARHP Annual Meeting
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Edward K.L. Chan¹, Jan Damoiseaux², Gabriel Carballo³, Karsten Conrad⁴, Wilson de Melo Cruvinel⁵, Paulo Francescantonio⁵, Marvin J. Fritzler⁶, Ignacio Garcia-De La Torre⁷, Manfred Herold⁸, Tsuneyo Mimori⁹, Minoru Satoh¹⁰, Carlos Von Muhlen¹¹, Luis E C Andrade¹² and representing committee and translation team members, ¹Dept of Oral Biology, University of Florida, Gainesville, FL, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Hospital Carlos G. Durand, Buenos Aires, Argentina, ⁴Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁵Pontifícia Universidade Católica de Goiás, Goiânia, Brazil, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ⁸Medical University of Innsbruck, Innsbruck, Austria, ⁹Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Rheumatology, Rheuma Clinic Dr. von Muhlen, Porto Alegre, Brazil, ¹²Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) pattern observed in the antinuclear antibody (ANA) test provides an initial assessment of autoantibody responses in candidate patients who have…
Abstract Number: 1895 • 2016 ACR/ARHP Annual Meeting
Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Boyang Zheng¹, Normand Blais², Jean-Luc Senécal³, Gemma Perez⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ²Hematology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ³Université de Montréal, Montréal, QC, Canada, ⁴Laboratory of autoimmunity, Centre de Recherche du CHUM, Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Platelet factor 4 (PF4), also called CXLC4 is a chemokine that is found in higher levels in systemic sclerosis (SSc) patients and is in…
Abstract Number: 2851 • 2016 ACR/ARHP Annual Meeting
An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Donald Massenburg, Justine Oldenberg, Amanda Sell, Tristan Krause and Alvin F. Wells, Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: The SLE-key® test to Rule Out lupus was developed by ImmunArray Ltd using serum samples of 246 SLE patients and 252 self-declared healthy controls.…
Abstract Number: 813 • 2016 ACR/ARHP Annual Meeting
Identifying and Assessing Subgroups in Systemic Sclerosis Patients Based on Comprehensive Autoantibody Profiling
Petra Budde¹, Hans-Dieter Zucht¹, Heike Göhler¹, Klaus Marquart¹, Peter Schulz-Knappe¹, Matthias Schneider² and Nicolas Hunzelmann³, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ³Department of Dermatology, University of Cologne, Cologne, Germany
Background/Purpose: Systemic sclerosis (SSc) is a remarkably heterogeneous autoimmune disease, for which effective disease-modifying therapies are still lacking. The most widely used classification divides SSc…
Abstract Number: 1900 • 2016 ACR/ARHP Annual Meeting
Anti-Topoisomerase Positive Systemic Sclerosis – Prognosis Infaust?
Maaike Boonstra¹, Gaia A. Beerends², Hans U. Scherer², Tom W.J. Huizinga¹ and Jeska K. de Vries-Bouwstra¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-topoisomerase antibodies (ATA) in systemic sclerosis have been associated with poorer prognosis including diffuse skin involvement, pulmonary fibrosis, cardiac involvement and increased mortality. However,…
Abstract Number: 2857 • 2016 ACR/ARHP Annual Meeting
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Jessica Schreiter¹, Jarrat Jordan¹, Matteo Cesaroni¹, Marc Chevrier², Alexa Piantone³, Ian Gourley³, Jacqueline Benson¹ and Takahiro Sato¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³Immunology Translational Medicine, Janssen Pharmaceutical Research and Development, LLC, Spring House, PA
Background/Purpose: Type I IFN (IFN-I)-regulated gene expression is known to be elevated in blood and skin lesions of patients with two different forms of cutaneous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].